Staccato Zaleplon Single Dose Pharmacokinetics

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of the study is to determine the safety, tolerability and pharmacokinetics of zaleplon delivered by the Staccato thermal aerosol system in healthy volunteers

Key facts

Study ID

NCT00620620

Run by

Alexza Pharmaceuticals, Inc.

People needed

40

Starts

2008-02-01

Expected to finish

2008-03-01

Last updated by the study team

2017-03-14

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male and female subjects between the ages of 18 to 55 years, inclusive who are in good general health

You may not qualify if…

• Subjects with a history of allergy or intolerance to zaleplon. Subjects who have any other disease or condition, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results.

Where it is running

• Covance Clinical Research Unit Inc. — Evansville, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.